Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company pioneering precision oncology solutions through innovative target discovery and therapeutic development. This page provides authorized updates on their research programs, clinical trials, and strategic initiatives in cancer treatment innovation.
Investors and researchers will find verified information about TNGX's pipeline progress, including PRMT5 inhibitor developments for CNS/non-CNS cancers and discontinued programs like TNG348. All content undergoes strict verification to ensure accuracy in reporting scientific milestones and regulatory updates.
Key coverage areas include clinical trial phases, research collaborations, peer-reviewed study publications, and corporate developments. The resource is particularly valuable for tracking therapies addressing tumor suppressor gene restoration and immune evasion mechanisms.
Bookmark this page for real-time updates on Tango Therapeutics' work in CRISPR-enabled drug discovery and their mission to transform cancer treatment paradigms through precision medicine approaches.
Tango Therapeutics (NASDAQ: TNGX) announced the acceptance of five abstracts for poster presentation at the AACR Annual Meeting 2025 in Chicago. The presentations will showcase preclinical data focusing on their PRMT5 inhibitor programs, particularly TNG456 and TNG462, designed for treating MTAP-deleted cancers.
The research highlights include evaluation of CNS drug penetration, brain-penetrant capabilities, combination therapy potential with KRAS-inhibitors, and analysis of MTAP truncations impact. Additionally, the company will present findings on tumor regression in FOCAD-deleted cancers through HBS1L/PELO complex disruption.
According to Dr. Adam Crystal, President of Research and Development, the data demonstrates the potential of their molecules as standalone treatments and combination partners in MTAP-deleted cancers, suggesting future development opportunities.
Tango Therapeutics (NASDAQ: TNGX) has reported its Q4 and full year 2024 financial results with several key developments. The FDA granted Orphan Drug Designation to TNG462 for pancreatic cancer treatment and cleared the IND application for TNG456, their brain-penetrant PRMT5 inhibitor.
The company established a clinical collaboration with Eli Lilly to evaluate TNG456 in combination with Verzenio. Early data for TNG462 showed durable clinical responses across multiple cancer types, including partial responses in pancreatic and lung cancer.
Financial highlights include:
- Cash position of $257.9M as of December 31, 2024
- Q4 2024 collaboration revenue of $4.1M vs $5.4M in Q4 2023
- Net loss of $37.7M ($0.35 per share) in Q4 2024
- Full-year net loss of $130.3M ($1.19 per share)
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in three major investment bank conferences in early 2025.
The company will participate in:
- The B Riley Precision Oncology & Radiopharma Conference in New York, featuring a panel discussion on 'Pushing Tumors Over the Edge with Synthetic Lethality' on February 28 at 9:00 AM ET
- The Leerink Global Healthcare Conference in Miami, hosting a fireside chat on March 12 at 2:20 PM ET
- The Barclays 27th Annual Global Healthcare Conference in Miami on March 13, available for one-on-one meetings
Webcasts will be available on the company's website under the 'Events & Presentations' tab, with replays archived for 90 days post-presentation.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in the upcoming Guggenheim SMID Cap Biotechnology Conference. Barbara Weber, M.D., the company's President and CEO, will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:00 AM ET.
The event will be accessible through a live webcast, available at the provided link and through the company's website under the 'Events & Presentations' section of the Investors page. The presentation recording will remain available on Tango's website for 90 days following the event.
Tango Therapeutics (NASDAQ: TNGX) announced that its Compensation Committee granted equity awards to a new employee under its 2023 Inducement Plan. The grants include a non-qualified stock option to purchase 187,500 shares at $3.89 per share and 31,250 restricted stock units (RSUs). The stock options will vest 25% on November 18, 2025, with remaining shares vesting monthly over 36 months. The RSUs will vest in three tranches: 10,416 shares in 2025, 10,417 shares in 2026, and 10,417 shares in 2027, subject to continued employment.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, announced that their President of Research & Development, Adam Crystal, M.D., Ph.D., will present at the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Thursday, December 5, 2024, at 1:30 PM ET. A live webcast will be available on the company's website under the 'Events & Presentations' section, with a replay accessible for 90 days after the event.
Tango Therapeutics (NASDAQ: TNGX) reported Q3 2024 financial results and business updates. The company highlighted positive clinical activity for TNG462 across multiple tumor types, including a 43% ORR in cholangiocarcinoma. A new clinical collaboration with Revolution Medicines was established to evaluate TNG462 combinations. The company reported $293.3 million in cash, with runway into Q3 2026. Q3 2024 financial results showed collaboration revenue of $11.6 million and a net loss of $29.2 million ($0.27 per share). R&D expenses increased to $33.3 million, up from $27.1 million in Q3 2023.
Tango Therapeutics announced positive updates on its PRMT5 program. TNG462 showed promising clinical activity in multiple tumor types, including NSCLC and pancreatic cancer, with patients maintaining treatment for a median of 24 weeks. The company will advance TNG462 into full development and plans multiple combination studies in 1H 2025. While discontinuing TNG908 enrollment due to insufficient CNS exposure in glioblastoma, Tango is introducing TNG456, a next-generation brain-penetrant PRMT5 inhibitor with enhanced potency, set to enter clinical trials in 1H 2025. A clinical collaboration with Revolution Medicines was established to evaluate TNG462 in combination with RAS(ON) inhibitors.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in two upcoming investor conferences. Barbara Weber, M.D., President and CEO of Tango Therapeutics, will represent the company at these events:
1. 2024 Wells Fargo Healthcare Conference on September 4, 2024, at 12:45 PM ET in Boston, MA.
2. 2024 Cantor Global Healthcare Conference on September 17, 2024, at 9:10 AM ET in New York, NY.
Live webcasts of the presentations will be available on the company's website under the 'Events & Presentations' tab on the 'Investors' page. Replays will be archived for 90 days following each presentation.
Tango Therapeutics (NASDAQ: TNGX) reported Q2 2024 financial results and business highlights. Key points include:
1. Ongoing dose expansion in TNG908 and TNG462 phase 1/2 clinical trials, with a comprehensive PRMT5 program update expected in 2H 2024.
2. TNG260 phase 1/2 clinical trial patient enrollment continues.
3. Strong cash position of $322.1 million as of June 30, 2024, with runway into 2027.
4. Q2 2024 financial results: Collaboration revenue $7.8 million, license revenue $12.1 million, R&D expenses $38.7 million, G&A expenses $10.8 million, net loss $25.6 million ($0.24 per share).
5. Gilead licensed a drug discovery program for a $12.0 million fee in June.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
